Skip to main content

Table 2 Demographic data for patients included in the analysis

From: Clinical advantages of a newly launched anti-thrombotic PMMA membrane for the nutritional status and dialysis-related symptoms in older chronic dialysis patients: a multicenter pilot study

Items

NFgroup

n

Control group

n

p

 Number of patient

15

 

14

  

 Sex (male/female)

9/6

15

11/3

14

n.s.a

 Age (year)

76.1 ± 5.0 (70.0–87.0)

15

74.7 ± 4.2 (70.0–87.0)

14

n.s.b

 Dialysis vintage (year)

9.8 ± 9.1 (0.5–30.0)

15

6.5 ± 4.2 (1.0–13.0)

14

n.s.c

 Dry weight (kg)

52.0 ± 9.1 (33.8–63.5)

15

57.8 ± 11.4 (43.2–90.0)

14

n.s. b

 Albumin concentration before dialysis (g/dL)

3.7 ± 0.3 (3.1–4.0)

15

3.6 ± 0.2 (3.3–4.1)

13

n.s. b

Dialysis condition

     

 Blood flow rate (mL/min)

217.3 ± 28.4 (200–300)

15

220.0 ± 22.2 (200–250)

14

n.s. b

 Dialysis time (h)

4.1 ± 0.3 (4.0–5.0)

15

4.1 ± 0.3 (4.0–5.0)

14

n.s. b

 Effective surface area (m2)

1.7 ± 0.3 (1.3–2.1)

15

1.8 ± 0.3 (1.5–2.1)

14

n.s. b

 Dialysis membrane (PS/PES/PEPA)

(8/5/2)

15

(12/1/1)

14

n.s. a

 Classification of dialyzer# (I·II/III/IV/V)

(0/0/8/7)

15

(0/4/5/5)

14

n.s. a

 Dialysate (with acetate/without acetate)

(9/6)

15

(13/1)

14

p < 0.05 a

Medical history

     

 Diabetes mellitus (Y/N)

(6/9)

15

(3/11)

14

n.s. a

 Cerebrocardiovascular event (Y/N)

(3/12)

15

(4/10)

14

n.s. a

  1. Results are presented as the mean ± standard deviation, and the values in parentheses represent the minimum and maximum values
  2. #Classification of dialyzers in the Japanese reimbursement system
  3. aChi-square test
  4. bUnpaired t test
  5. cWelch’s test